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Abstract
Wharton's jelly from the umbilical cord is a noncontroversial source of mesenchymal stem cells
(WJMSCs) with high plasticity, proliferation rate and ability to differentiate towards multiple
lineages. WJMSCs from different donors have been characterized for their osteogenic potential.
Although there is large evidence of WJMSCs plasticity, recently scientific debate has focused on
MSCs selection, establishing predictable elements to discriminate the cells with most promising
osteoprogenitor cell potential.
In the present study a comparative study between the presence of osteoblastic markers and
different parameters that pertain to both the newborn and the mother was performed. Umbilical
cords were collected after all patients signed the informed consent and local ethical commettee
approved the study. Obstetric parameters, including baby's gender and birth weight, mother's age
at delivery, gestational stage at parturition and mode of delivery were examined. After
characterization and expansion, WJMSCs were analyzed for two osteoblastic markers, alkaline
phosphatase (ALP) activity, and the expression level of RUNX-2 transcription factor, and for their
ability to deposit mineralized matrix after osteogenic induction.
We found that osteoblastic potential was not influenced by baby's gender and mode of delivery.
On the contrary, the highest degree of osteoblastic potential has been shown by WJMSCs with
RUNX-2 high basal levels, selected from umbilical cords of the heaviest term babies.
Even if further evaluation is required, our hypothesis is that our findings may help in selecting the
optimal umbilical cord donors and in collecting high potential Wharton's jelly-derived
osteoprogenitors efficiently.
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Background
The umbilical cord is a noncontroversial source of mesen-
chymal stem cells (MSCs) [1,2]. Recently MSCs isolated
from Wharton's Jelly (WJMSCs), a mucoid connective tis-
sue of the umbilical cord, were shown to have the ability
to differentiate towards multiple lineages, including adi-
pose, bone, and neuronal lineages [3,4].
Work from several laboratories suggests that these cells,
which are very abundant, have potential in therapeutic
and tissue engineering field, and indicates that they may
be successfully collected and stored for both preclinical
work, and banking services [5,6].
It is important to point out that patients who receive
umbilical cord stem cells are at a lower risk of developing
graft versus host disease, than those who receive bone
marrow transplants [7].
Even if there is a considerable debate about MSC plastic-
ity, there are numerous recent reviews and papers on
MSCs describing molecular signals that have been identi-
fied in driving MSC differentiation down osteoblast line-
age, and molecules that are known playing an important
role in achieving the desired cellular response such as
bone morphogenetic proteins (BMP), dexamethasone,
ascorbic acid, and β-glycerophosphate [8,9]. Bone defect
repair has been one of the first applications of MSCs, and
clinical potential of the use of these cells for bone tissue
repair is now extensively explored [10-13].
Nevertheless, bone tissue engineering applications require
that MSCs must possess certain reproducible characteris-
tics such as maintenance of the differentiated phenotype.
In this scenario, an area of intense research activity, is
devoted to improve human MSC characterization, isola-
tion, and expansion [14-16].
Starting from these considerations, we sought to establish
further elements for selection of the most desirable cell
source for obtaining, inside a WJMSCs collection, the cells
with most promising ability to differentiate into osteob-
lasts.
In the present study five different obstetric parameters,
including baby's gender and birth weight, mother's age at
delivery, gestational stage at parturition and mode of
delivery, were correlated with osteoblastic markers, such
as ALP activity, RUNX-2 expression and with the ability of
WJMSCs to differentiate along osteogenic lineage.
The hypothesis that the correlation among these parame-
ters may help the selection of optimal umbilical cord
donors to collect WJMSCs with most promising osteopro-
genitor cell potential is discussed.
Discussion
Human umbilical cord collection and WJMSCs analysis
Human umbilical cord and umbilical cord blood taken
after delivery of the newborn, from samples that would be
inevitably discarded, have been regarded as an alternative
source for transplantation and therapy because of their
haematopoietic and mesenchymal cell components [14].
The increasing interest in mesenchymal progenitors for
tissue repair widely promoted the characterization of early
predictive parameters for plasticity, inducibility and prac-
tical utility of these cells [10].
As previously reported [17] Wharton's jelly is an ideal and
uncontroversial source for mesenchymal stem cells (WJM-
SCs) due to the simple collection procedure and the high
homogeneity of cell population which is obtained.
In this study, we prepared primary cultures of WJMSCs
from 60 donating subjects whose characteristics are
shown in Table 1. Five obstetric factors, including baby's
gender and birth weight, mother's age at delivery, gesta-
tional stage at parturition and mode of delivery were
examined. By flow cytometric analysis (Figure 1A and 1B)
and double staining with propidium iodide (PI) and Cal-
cein-AM (Figure 1C) before and after cryopreservation, we
demonstrated that all WJMSCs samples showed a compa-
rable mesenchymal property and the same level of viabil-
ity. These characteristics indicate that the quality of the
cells is not influenced by the examined obstetric factors.
In order to assess the effect of these maternal and neonatal
factors on osteoblastic potential of WJMSCs, we focused
on the WJMSCs showing the highest levels of mesenchy-
mal and adhesion markers (CD90/Thy-1, CD29/β-1
integrin, CD44/hyaluronan receptor, and CD105/SH2,
endoglin), but not expressing hematopoietic/endothelial
markers (CD34 and CD45). 20 samples were induced to
osteoblast differentiation (see legend of Figure 2), and the
propensity to differentiate into osteoblasts was demon-
strated through the different ability of the cells to deposit
mineralized matrix. A very high heterogeneity in response
to treatment with osteogenic medium was observed, and
all attempts to detect a correlation between this ability
and one of the examined clinical parameters met not suc-
cess. It is important to underline that heterogeneity in the
behaviour of our WJMSC samples is in agreement with the
data obtained by other researchers [18,19] and suggests
that a great variability is often present after the recover of
these staminal cells.
WJMSCs and osteoblastogenesis
On the basis of these observations, we conducted further
analyses adjusting for two specific markers of osteoblast
differentiation: the activity of Alkaline Phosphatase (ALP)
[20] and the expression levels of Runt-related transcrip-
tion factor 2 (RUNX-2) which increases transcription ofReproductive Biology and Endocrinology 2009, 7:106 http://www.rbej.com/content/7/1/106
Page 3 of 7
(page number not for citation purposes)
Table 1: Characteristics of subjects
Sample Mother's age (ys) Weeks of
pregnancy
Mode of delivery Gender Birth weight (Kg)
1 26 29 CS F 1.25
2 31 32 CS M 1.74
33 0 4 0 C S F 3
43 0 3 2 C S M1 . 9
5 30 32 CS M 1.91
6 37 40 SP F 3.59
7 21 41 SP F 3.75
8 35 40 SP F 3.17
9 33 42 SP M 3.05
10 31 40 SP M 3.69
11 38 38 CS F 3.32
12 38 38 CS F 2.6
13 38 39 SP M 3.45
14 36 40 SP F 3.6
15 29 40 CS F 3.22
16 33 38 SP M 3.7
17 34 38 CS F 3.45
18 35 35 CS M 3.31
19 34 40 SP M 3.21
20 35 40 SP M 3.18
21 32 38 CS F 3.6
22 33 35 CS M 2.41
23 33 35 CS M 2.53
24 40 40 SP F 3.75
25 38 39 SP M 3.36
26 29 37 CS F 3.62
27 29 40 SP M 3.4
28 39 39 CS M 3.62
29 33 40 SP F 3.12
30 32 35 SP F 3.17
31 29 37 CS M 2.14
32 37 39 CS M 3.37
33 20 40 SP F 3.02
34 41 39 CS F 2.73
35 35 37 CS F 2.77
36 34 38 CS F 2.9
37 38 38 SP F 3.05
38 34 40 SP M 3.7
39 32 36 SP M 2.93
40 27 38 SP M 3.1
41 30 34 SP M 2.6
42 31 41 SP F 3.25
43 27 33 CS M 1.915
44 27 33 CS F 2.005
45 26 39 SP M 3.35
46 34 42 CS M 3.51
47 23 37 CS F 2.95
48 30 39 CS M 4.24
49 33 39 CS F 3.3
50 37 39 CS M 2.84
51 33 39 CS M 3.27
52 32 40 CS M 3.9
53 31 37 CS F 1.98
54 35 40 SP M 3.95
55 23 37 SP M 3.11
56 40 38 CS M 2.85
57 37 39 CS F 3.3
58 25 35 CS M 3.57
59 25 35 CS F 2.38
60 27 29 CS M 2.1
The recorded clinical parameters are: mother's age, weeks of pregnancy, mode of delivery, newborn gender and birth weight.
F (female) M (male) CS (caesarian delivery) SP (spontaneous delivery)
Umbilical cords were collected, after mothers' consent and approval of "Ethical commettee of University of Ferrara" and "Ethical commettee of 
Sant'Anna Hospital". The study population consisted of 60 healthy pregnant women voluntary enrolled between February 1, 2008 and March 1, 
2009.Reproductive Biology and Endocrinology 2009, 7:106 http://www.rbej.com/content/7/1/106
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osteoblast specific genes [17]. As shown in Figure 2A,
focusing on basal levels of ALP and RUNX-2, it has been
possible to demonstrate that these parameters can be pre-
dictive of osteoblastic potential of WJMSCs. In fact, the
samples with high basal levels of RUNX-2 and ALP are
more prone to deposit mineral matrix if compared to
WJMSC with low levels of these two proteins. These obser-
vations suggest that it may be possible to discriminate
among different WJMSC samples those will have a posi-
tive outcome towards osteoblastic differentiation.
Osteoblastogenesis and clinical parameters
In a next step, we analyzed whether the basal levels of
RUNX-2 and ALP correlate with the examined obstetrics
factors (Figure 2B). We found that the infant gender and
mode of delivery didn't significantly correlate (P > 0.05)
with basal RUNX-2 expression and ALP activity. On the
other hand, the age of the mother at delivery, has a signif-
icant impact on the basal ALP activity but doesn't affect
RUNX-2 expression level. Samples collected from mothers
which were <32 years old give origin to WJMSCs with high
Small pieces (2-3 mm2) of cords were processed within 4 hours and cultured in DMEM-LG Figure 1
Small pieces (2-3 mm2) of cords were processed within 4 hours and cultured in DMEM-LG. At ~70-80% conflu-
ence, cells were scraped off by 0.05% trypsin/EDTA (Gibco, Grandisland, USA), and analyzed for expression of mesenchymal 
stem cell surface markers [17], by flow cytometric analysis, as reported (representative experiment) in panel A. The gated cells 
were negative for the hematopoietic line markers CD45 and CD34, partially positive for CD105 and CD44, and positive for 
the mesenchymal stem cells markers CD90 and CD29. B) Schematical distribution of the cell surface parameters of the 60 
samples analyzed. C) Comparison of the cell culture viability before and after thawing of a cryopreserved sample (high and low 
panel, respectively). The viability of WJMSCs analyzed by double staining with propidium iodide (PI) and Calcein-AM (Cellstain 
double staining kit, Sigma Aldrich, St Luis, MO, USA) is indicated. Cells were propidium iodide stained and then analyzed, 
before and after cryopreservation, for their DNA content, by using BD Immunocytometry Systems DNA QC Particles (BD, 
New Jersey, USA). The cytofluorimetric profile was analyzed and the percentage of the cell population distribution in the dif-
ferent phases has been reported.Reproductive Biology and Endocrinology 2009, 7:106 http://www.rbej.com/content/7/1/106
Page 5 of 7
(page number not for citation purposes)
After characterization in terms of mesenchymal stem cell surface markers expression and cell viability, the osteogenic differen- tiation of WJMSCs was assessed in the first- and second-passage cultures Figure 2
After characterization in terms of mesenchymal stem cell surface markers expression and cell viability, the 
osteogenic differentiation of WJMSCs was assessed in the first- and second-passage cultures. Cells were cultured 
for 21 days in Osteogenic Differentiation Medium (Osteogenic BulletKit, PT-3924 & PT-4120, Lonza, Basel, Switzerland) or in 
DMEM-LG as a control. The ability of the cells to become mature osteoblasts was evaluated in terms of mineral matrix depo-
sition assessed by Alizarin Red staining (AR-S, Sigma Aldrich, St Luis, MO, USA). The cells fixed in 70% ethanol for 1 h at room 
temperature, were washed with PBS, stained with 40 mM AR-S (pH 4.2) for 10 min at room temperature, washed five times 
with deionized water and incubated in PBS for 15 min to eliminate non-specific staining. The stained matrix was then observed 
at different magnification using a Leitz microscope. In panel A the mineralization status (+, positive or -, negative) was corre-
lated with the basal level (at day ''0'') of RUNX-2 expression and ALP activity. RUNX-2 expression was examined by quantita-
tive TaqMan (ABI PRISM 7700, Applied Biosystems Inc, Foster City, CA, USA) RT-PCR (Assay-on-demand, Hs00231692_m1). 
The data were normalized on the basis of GAPDH expression and reported as relative mRNA expression levels. ΔΔCt method 
was used to compare gene expression data. ALP activity was measured by the hydrolysis of p-nitrophenylphosphate (PNPP, 
Sigma Aldrich, St Luis, MO, USA) [22] and one unit was defined as the amount of enzyme which hydrolyzed 1 μmol/PNPP per 
minute. Cell protein content was determined according to the Lowry method [23]. (* = P < 0.05). B) Relationship between 
molecular and obstetric parameters. Basal levels of RUNX-2 expression and ALP activity were related to mother's age, weeks 
of pregnancy and birth weight in 20 WJMSC samples. C) The 20 samples of panel B were subdived in the two reported sub-
groups: premature birth (subgroup I) and full term birth (subgroup II). All examined molecular and obstetric parameters are 
reported. F (female), M (male), CS (Caesarian delivery), SP (spontaneous delivery). D) The ability to deposit mineralized matrix 
was valuated at the indicated times (0, 14, 21 days) in two representative samples of the two subgroups, by Alizarin red stain-
ing.Reproductive Biology and Endocrinology 2009, 7:106 http://www.rbej.com/content/7/1/106
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ALP activity. Interestingly, birth weight of the infant was
shown to significatively impact on RUNX-2 basal expres-
sion level which, as reported in Figure 2B, decreases with
the decreasing of the baby's weight. The same relationship
was found for the duration of pregnancy. In fact, it was
found that WJMSCs from babies born before the 37 weeks
of gestation express lower basal level of RUNX-2 than the
full term borns. It is very likely that WJMSCs recovered
from premature birth contain a high number of undiffer-
entiated cells with high plasticity, a condition which is not
actually required for osteoblast differentiation.
As a whole, these findings led us to focus on two parame-
ters, weeks of pregnancy and consequently birth weight of
the baby, and RUNX-2 basal levels, subdividing the col-
lected samples in the two subgroups reported in Figure
2C: subgroup I, premature birth with low levels of RUNX-
2, and subgroup II, full term birth with high levels of
RUNX-2. The ability of the samples belonging to these
two subgroups to complete the event of cellular matura-
tion, that is the deposition of mineralized matrix, was
then compared. Two representative samples of the two
subgroups (Figure 2D) demonstrate that, samples from
subgroup I showed a null mineralization status also after
21 day of cell culture in osteogenic medium, whereas sam-
ples from subgroup II showed a high level of mineraliza-
tion beginning from day 14. These findings suggest that
maximal WJMSCs osteoblastic potential can be obtained
by primary cultures with RUNX-2 high basal levels,
selected from the heaviest term babies.
Another clinical observation that is important to do is that
the cases below 37 weeks of gestation were all treated with
24 mg of bethametasone two hours before delivery. Such
a therapy is routinely given to all the pregnant women
delivering prematurely in order to prevent respiratory dis-
tress syndrome in the newborns. Therefore, a possible
influence of this hormone on stem cells behaviour can be
hypothesized. At this regard it has been recently reported
that glucocorticoids play an essential role in favouring
stem cells differentiation towards adipocyte lineage, thus
inhibiting bone and muscle lineages [21]. Such an influ-
ence appears to be exerted by inducing myostatin, a
potent molecule that regulates muscle development.
Therefore, based on the above evidences a possible
absence of osteoblastogenesis could have been expected
in the samples derived from women delivering prema-
turely. Since we observed a low or null mineralization sta-
tus in WJMSCs from such patients, it could be possible to
point out a correlation between the two events. However,
our analysis showed that this evidence is not always occur-
ing, indicating that the short term high dose of
bethametasone administered wasn't ever effective in
inhibiting bone lineage.
Conclusion
To conclude, we should indicate that the analysis of the
basal level of RUNX-2 and ALP activity may allow a quick
testing of a high number of mesenchymal precursors cul-
tured in vitro and select the more suitable to potentially
use for bone tissue engineering application. In addition,
for the same aim, our results suggest that it is preferred to
recruit the samples from full term borns without paying
attention to mother's age.
Even if further evaluation is required, our hypothesis is
that our findings may help in selecting the optimal umbil-
ical cord donors and in collecting high potential Whar-
ton's jelly-derived osteoprogenitors efficiently.
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